New Cell therapy Will Transplanted Organ Rejection

Researchers from the University of Oxford developed a cell therapy that could prevent transplanted organs from being rejected by the body and remove the need for patient's long term drug treatment

By Iddo Genuth

May 23, 2011

The innovative approach will work by re-injecting patients with their own immune cells after the cells have been isolated from a blood sample. The cells would be grown in the laboratory under conditions that will make them "learn" not to reject the transplant.

The current research was able to prevent rejection of a transplanted piece of blood vessel in a mouse model . Dr. Andrew Bushell of the Nuffield Department of Surgical Sciences at the University of Oxford, who headed the research said: "We have developed a new approach to generate cells called regulatory T cells that can control rejection of transplanted tissue in mice".

Although modern organ transplantation is considered to be fairly effective, patients are required to take strong drugs for the rest of their lives to make sure the organ is not rejected by the body's immune system. However it is knwon that long-term use of these drugs can lead to an increased risk of infection, cancer, damage to blood vessels, and metabolic complications.

Human T cells (aka Tregs) are known to dampen down immune responses when they are no longer needed and help to maintain the body's immune system. According to Dr Bushell: "If we can grow regulatory T cells in the laboratory and teach them to turn off immune cells that are attacking a transplant, we may be able to use these cells to control transplant rejection".

The method developed by Dr Bushell and his team isolates human T cells and cultured in the lab with an existing drug called cilostamide and cells from the tissue being transplanted back into the patient. The researchers then showed that the human regulatory T cells produced using this method could control transplant rejection in a mouse model with a human-like immune system.

The new cell therapy is likely to be used initially in living donor transplantation, where for example a person donates a kidney to a relative, spouse or close friend. This type of donation is now very widespread because of the shortage of organs from deceased donors.

A blood sample would be taken from the patient a few weeks before the operation so that the Tregs could be grown and tested in the laboratory before being given back to the patient. The transplant operation would then be carried out as normal and special drugs will be given to control early rejection. But later on the drugs could be steadily withdrawn until they were no longer needed.

According to Dr Bushell it will still take between 3-5 years before trials of cell therapy in human transplantation could begin.

Copyright © 2007 The Future of Things.

This article posted August 28, 2011.